Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

IMNM - Immunome, Inc. Последние новости | Finranks

Home

IMNM

(IMNM)

NCM – Цена в реальном времени. Валюта: USD

19.61

-0.80 (-3.92%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

19.27

-0.34 (-1.73%)

После закрытия: Mar 27, 2026, 5:09 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Immunome: Upcoming NDA, Valuation, And Investment Case

Immunome: Upcoming NDA, Valuation, And Investment Case

Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE data. Varegacestat demonstrated superior efficacy and safety versus nirogacestat, with an 84% risk reduction in progression or death and a 56% objective response rate. Despite a small addressable market (~3,000 patients), conservative peak global sales are estimated at $280 million, supporting a valuation over 235% above IMNM's current market cap.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company's 2024 Induc.

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Sold all 3,185,000 shares of Immunome, estimated at $37.30 million based on quarterly average pricing Quarter-end position value decreased by $37.30 million, reflecting both stock price movement and the sale Represents a 4.92% decrease in Opaleye Management's 13F reportable assets under management Post-trade, Opaleye Management holds zero shares and zero dollar value in Immunome The position accounted for 5.3% of fund AUM in the prior quarter, marking a significant shift in portfolio composition

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. “Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in.

Immunome to Present at Upcoming Investor Conferences

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can ac.

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 million, reflecting both share purchases and price changes.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Induce.

Видео

No Data

There is no data to display